38.30 0.00 (0.00%)
After hours: 4:18PM EDT
|Bid||35.00 x 39400|
|Ask||0.00 x 1000|
|Day's Range||38.03 - 38.41|
|52 Week Range||30.20 - 39.45|
|PE Ratio (TTM)||116.06|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.41|
Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.
CE-marked workflow enables efficient, high-throughput screening for tuberculosis control efforts in Europe and other markets; introduction in United States expected in 2019 and Chi
QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $100 million.
Today, Pacific Biosciences of California (PACB) is trading at $5.16 per share, up ~6.17% from yesterday’s close of $4.86. On September 12, Pacific Biosciences stock closed at $4.86, a 6.46% increase from its September 11 closing price of $4.57. Its September 12 stock price represented an ~141.0% rise from its 52-week low of $2.02 on April 2. Its stock price hit its 52-week high of $5.58 on October 3, 2017.
Frankfurt Prime Standard: QIA) announced today that its global shares will be included in Germany’s MDAX index as of September 24, 2018, in addition to the current listing in the country’s TecDAX index. The addition to the MDAX – which will now track the next 60 largest companies on the German stock market after the 30 largest stocks in the DAX index – comes as part of a reorganization of index rules adopted by Deutsche Boerse, operator of the Frankfurt Stock Exchange.
A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $128 million.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / QIAGEN NV (NYSE: QGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 9:00:00 AM Eastern Time. To listen ...
Day-one lab readiness speeds commercialization and reimbursement in personalized medicine
Frankfurt Prime Standard: QIA) today announced that its careHPV™ Test, one of the only molecular diagnostics for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer, so screening women for the presence of the virus is a critical aspect for prevention and early treatment of the deadly cancer.
Qiagen (QGEN) delivered earnings and revenue surprises of 3.13% and 0.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Venlo, Netherlands-based company said it had net income of 16 cents. Earnings, adjusted for non-recurring costs, came to 33 cents per share. The results exceeded Wall Street expectations. ...
Collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection
QIAGEN N.V. plans as previously announced to release its report on results for the second quarter 2018 on Tuesday, July 31 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .